Johnson & Johnson and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday.
Under the agreement the company will commit approximately $604 million and the HHS Department's Biomedical Advanced Research and Development Authority will commit about $454 million to support the Phase 3 ENSEMBLE trial evaluating Janssen's investigational COVID-19 vaccine candidate as a single dose in up to 60,000 volunteers worldwide, the company said in a statement
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled" What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine US Congress Leaders Agree On Deal To Avoid Government Shutdown Budget 2024 LIVE Updates: Nirmala Sitharaman's Big Jobs And Tax Announcements In Budget Speech New Tax Regime Slabs Changed, Standard Deduction Up From Rs 50,000 To 75,000 Budget 2024: What Is Cheaper? Pic Of Indian Broom With "Nutrition Facts" Label Leaves Internet Chuckling Bihar And Andhra Pradesh Get Major Funding; Social Media Reacts With Memes New Tax Regime Slabs Changed, Standard Deduction Up From Rs 50,000 To 75,000 Track Latest News Live on NDTV.com and get news updates from India and around the world.